Study of phosphorylation events for cancer diagnoses and treatment

• Published in: Clinical and translational medicine Vol. 4; no. 1; pp. 1 - 8
• Main Authors: López Villar, Elena, Madero, Luis, A López-Pascual, Juan, C Cho, William
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.12.2015; John Wiley & Sons, Inc; Wiley
• Subjects: Clinical medicine; Commentary; Diagnosis; Medicine; Medicine & Public Health; Oncology; Proteomics; Treatment; Oncology; Treatment; Diagnosis; Proteomics
• ISSN: 2001-1326; 2001-1326
• DOI: 10.1186/s40169-015-0059-0

The activation of signaling cascades in response to extracellular and intracellular stimuli to control cell growth, proliferation and survival, is orchestrated by protein kinases via phosphorylation. A critical issue is the study of the mechanisms of cancer cells for the development of more effective drugs. With the application of the new proteomic technologies, together with the advancement in the sequencing of the human proteome, patients will therefore be benefited by the discovery of novel therapeutic and/or diagnostic protein targets. Furthermore, the advances in proteomic approaches and the Human Proteome Organization (HUPO) have opened a new door which is helpful in the identification of patients at risk and towards improving current therapies. Modification of the signaling-networks via mutations or abnormal protein expression underlies the cause or consequence of many diseases including cancer. Resulting data is used to reveal connections between genes proteins and compounds and the related molecular pathways for underlining disease states. As a delegate of HUPO, for human proteome on children assays and studies, we, at Hospital Universitario Niño Jesús, are seeking to support the human proteome in this context. Clinical goals have to be clearly established and proteomics experts have to set up the appropriate proteomic strategy, which coupled to bioinformatics will make it possible to achieve new therapies for patients with poor prognosis. We envision to combine our up-coming data to the HUPO organization in order to support international efforts to advance the cure of cancer disease.